Page 405 - Williams Hematology ( PDFDrive )

380 Part V: Therapeutic Principles Chapter 23: Hematopoietic Cell Transplantation 381

322. Yanik GA, Horowitz MM, Weisdorf DJ, et al: Randomized, double-blind, placebo- 348. Hatchette T, Tipples GA, Peters G, et al: Foscarnet salvage therapy for acyclovir-resis-
controlled trial of soluble tumor necrosis factor receptor: Enbrel (etanercept) for the tant varicella zoster: Report of a novel thymidine kinase mutation and review of the
treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: literature. Pediatr Infect Dis J 27:75–77, 2008.
Blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Trans- 349. Erard V, Guthrie KA, Varley C, et al: One-year acyclovir prophylaxis for preventing
plant 20:858–864, 2014. varicella-zoster virus disease after hematopoietic cell transplantation: No evidence of
323. Gilbert C, Vasu TS, Baram M: Use of mechanical ventilation and renal replacement rebound varicella-zoster virus disease after drug discontinuation. Blood 110:3071–
therapy in critically ill hematopoietic stem cell transplant recipients. Biol Blood Marrow 3077, 2007.
Transplant 19:321–324, 2013. 350. Chou JF, Kernan NA, Prockop S, et al: Safety and immunogenicity of the live attenuated
324. Alessandrino EP, Bernasconi P, Colombo A, et al: Pulmonary toxicity following carmust- varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic
ine-based preparative regimens and autologous peripheral blood progenitor cell trans- hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 17:1708–
plantation in hematological malignancies. Bone Marrow Transplant 25:309–313, 2000. 1713, 2011.
325. Reusser P, Attenhofer R, Hebart H, et al: Cytomegalovirus-specific T-cell immunity in 351. Hata A, Asanuma H, Rinki M, et al: Use of an inactivated varicella vaccine in recipients
recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood of hematopoietic-cell transplants. N Engl J Med 347:26–34, 2002.
89:3873–3879, 1997. 352. Billingham RE: The biology of graft-versus-host reactions. Harvey Lect 62:21–78, 1966.
326. Dulude G, Roy DC, Perreault C: The effect of graft-versus-host disease on T cell pro- 353. Ferrara JL, Levine JE, Reddy P, et al: Graft-versus-host disease. Lancet 373:1550–1561,
duction and homeostasis. J Exp Med 189:1329–1342, 1999. 2009.
327. Douek DC, Vescio RA, Betts MR, et al: Assessment of thymic output in adults after hae- 354. Spierings E, Kim YH, Hendriks M, et al: Multicenter analyses demonstrate significant
matopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-
355:1875–1881, 2000. matched related and unrelated hematopoietic stem cell transplantation. Biol Blood
328. Bosch M, Khan FM, Storek J: Immune reconstitution after hematopoietic cell trans- Marrow Transplant 19:1244–1253, 2013.
plantation. Curr Opin Hematol 19:324–335, 2012. 355. Spierings E: Minor histocompatibility antigens: Past, present, and future. Tissue Anti-
329. Collin BA, Leather HL, Wingard JR, et al: Evolution, incidence, and susceptibility of gens 84:374–360, 2014.
bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect 356. Behar E, Chao NJ, Hiraki DD, et al: Polymorphism of adhesion molecule CD31 and its
Dis 33:947–953, 2001. role in acute graft-versus-host disease. N Engl J Med 334:286–291, 1996.
330. Robenshtok E, Gafter-Gvili A, Goldberg E, et al: Antifungal prophylaxis in cancer 357. Sahaf B, Yang Y, Arai S, et al: H-Y antigen-binding B cells develop in male recipients of
patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic female hematopoietic cells and associate with chronic graft vs. host disease. Proc Natl
review and meta-analysis. J Clin Oncol 25:5471–5489, 2007. Acad Sci U S A 110:3005–3010, 2013.
331. van Burik JH, Leisenring W, Myerson D, et al: The effect of prophylactic fluconazole 358. Oostvogels R, Lokhorst HM, Minnema MC, et al: Identification of minor histocompati-
on the clinical spectrum of fungal diseases in bone marrow transplant recipients with bility antigens based on the 1000 Genomes Project. Haematologica 99:1854–1859, 2014.
special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine 359. Jagasia M, Arora M, Flowers ME, et al: Risk factors for acute GVHD and survival after
(Baltimore) 77:246–254, 1998. hematopoietic cell transplantation. Blood 119:296–307, 2012.
332. Marr KA, Crippa F, Leisenring W, et al: Itraconazole versus fluconazole for preven- 360. Filipovich AH, Weisdorf D, Pavletic S, et al: National Institutes of Health consensus
tion of fungal infections in patients receiving allogeneic stem cell transplants. Blood development project on criteria for clinical trials in chronic graft-versus-host disease:
103:1527–1533, 2004. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–
333. Ethier MC, Science M, Beyene J, et al: Mould-active compared with fluconazole pro- 956, 2005.
phylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy 361. Sale GE, Lerner KG, Barker EA, et al: The skin biopsy in the diagnosis of acute graft-
or haematopoietic stem-cell transplantation: A systematic review and meta-analysis of versus-host disease in man. Am J Pathol 89:621–636, 1977.
randomised controlled trials. Br J Cancer 106:1626–1637, 2012. 362. Firoz BF, Lee SJ, Nghiem P, et al: Role of skin biopsy to confirm suspected acute graft-vs-
334. Tomblyn M, Chiller T, Einsele H, et al: Guidelines for preventing infectious complica- host disease: Results of decision analysis. Arch Dermatol 142:175–182, 2006.
tions among hematopoietic cell transplantation recipients: A global perspective. Biol 363. Shimoni A, Rimon U, Hertz M, et al: CT in the clinical and prognostic evaluation of
Blood Marrow Transplant 15:1143–1238, 2009. acute graft-vs-host disease of the gastrointestinal tract. Br J Radiol 85:e416–e423, 2012.
335. Neiman P, Wasserman PB, Wentworth BB, et al: Interstitial pneumonia and cytomeg- 364. Ross WA, Ghosh S, Dekovich AA, et al: Endoscopic biopsy diagnosis of acute gastroin-
alovirus infection as complications of human marrow transplantation. Transplantation testinal graft-versus-host disease: Rectosigmoid biopsies are more sensitive than upper
15:478–485, 1973. gastrointestinal biopsies. Am J Gastroenterol 103:982–989, 2008.
336. Einsele H, Ehninger G, Hebart H, et al: Polymerase chain reaction monitoring reduces 365. Liu A, Meyer E, Johnston L, et al: Prevalence of graft versus host disease and cytomeg-
the incidence of cytomegalovirus disease and the duration and side effects of antiviral alovirus infection in patients post-haematopoietic cell transplantation presenting with
therapy after bone marrow transplantation. Blood 86:2815–2820, 1995. gastrointestinal symptoms. Aliment Pharmacol Ther 38:955–966, 2013.
337. Ljungman P, de La Camara R, Milpied N, et al: Randomized study of valacyclovir as 366. Kreisel W, Dahlberg M, Bertz H, et al: Endoscopic diagnosis of acute intestinal GVHD
prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone mar- following allogeneic hematopoietic SCT: A retrospective analysis in 175 patients. Bone
row transplants. Blood 99:3050–3056, 2002. Marrow Transplant 47:430–438, 2012.
338. Winston DJ, Yeager AM, Chandrasekar PH, et al: Randomized comparison of oral vala- 367. Shulman HM, Sharma P, Amos D, et al: A coded histologic study of hepatic graft-versus-
cyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after host disease after human bone marrow transplantation. Hepatology 8:463–470, 1988.
allogeneic bone marrow transplantation. Clin Infect Dis 36:749–758, 2003. 368. Storb R, Pepe M, Deeg HJ, et al: Long-term follow-up of a controlled trial comparing a
339. van der Heiden PL, Kalpoe JS, Barge RM, et al: Oral valganciclovir as pre-emptive combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis
therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous of graft-versus-host disease in patients administered HLA-identical marrow grafts for
ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant leukemia. Blood 80:560–561, 1992.
37:693–698, 2006. 369. Storb R, Leisenring W, Deeg HJ, et al: Long-term follow-up of a randomized trial of
340. Ruiz-Camps I, Len O, de la Camara R, et al: Valganciclovir as pre-emptive therapy for graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrex-
cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. ate alone in patients given marrow grafts for severe aplastic anemia. Blood 83:2749–
Antivir Ther 16:951–957, 2011. 2750, 1994.
341. Reusser P, Einsele H, Lee J, et al: Randomized multicenter trial of foscarnet versus gan- 370. Storb R, Pepe M, Anasetti C, et al: What role for prednisone in prevention of acute
ciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell graft-versus-host disease in patients undergoing marrow transplants? Blood 76:1037–
transplantation. Blood 99:1159–1164, 2002. 1045, 1990.
342. Marty FM, Winston DJ, Rowley SD, et al: CMX001 to prevent cytomegalovirus disease 371. Ratanatharathorn V, Nash RA, Przepiorka D, et al: Phase III study comparing metho-
in hematopoietic-cell transplantation. N Engl J Med 369:1227–1236, 2013. trexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for
343. Chemaly RF, Ullmann AJ, Stoelben S, et al: Letermovir for cytomegalovirus prophylaxis graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow trans-
in hematopoietic-cell transplantation. N Engl J Med 370:1781–1789, 2014. plantation. Blood 92:2303–2314, 1998.
344. Winston DJ, Young JA, Pullarkat V, et al: Maribavir prophylaxis for prevention of 372. Nash RA, Antin JH, Karanes C, et al: Phase 3 study comparing methotrexate and tacroli-
cytomegalovirus infection in allogeneic stem cell transplant recipients: A multicenter, mus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host dis-
randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111:5403– ease after marrow transplantation from unrelated donors. Blood 96:2062–2068, 2000.
5410, 2008. 373. Finke J, Bethge WA, Schmoor C, et al: Standard graft-versus-host disease prophy-
345. Marty FM, Ljungman P, Papanicolaou GA, et al: Maribavir prophylaxis for prevention laxis with or without anti-T-cell globulin in haematopoietic cell transplantation from
of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, matched unrelated donors: A randomised, open-label, multicentre phase 3 trial. Lancet
double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11:284–292, 2011. Oncol 10:855–864, 2009.
346. Blyth E, Clancy L, Simms R, et al: Donor-derived CMV-specific T cells reduce the 374. Socie G, Schmoor C, Bethge WA, et al: Chronic graft-versus-host disease: Long-term
requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplanta- results from a randomized trial on graft-versus-host disease prophylaxis with or with-
tion. Blood 121:3745–3758, 2013. out anti-T-cell globulin ATG-Fresenius. Blood 117:6375–6382, 2011.
347. Erard V, Wald A, Corey L, et al: Use of long-term suppressive acyclovir after hemato- 375. Kanakry CG, Tsai HL, Bolanos-Meade J, et al: Single-agent GVHD prophylaxis with
poietic stem-cell transplantation: Impact on herpes simplex virus (HSV) disease and posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for
drug-resistant HSV disease. J Infect Dis 196:266–270, 2007. AML, ALL, and MDS. Blood 124:3817–3827, 2014. .

Kaushansky_chapter 23_p0353-0382.indd 380 9/19/15 12:47 AM